These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20473889)

  • 1. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
    Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
    Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
    Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
    Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses.
    Toda M; Wang L; Ogura S; Torii M; Kurachi M; Kakimi K; Nishikawa H; Matsushima K; Shiku H; Kuribayashi K; Kato T
    Int J Cancer; 2011 Sep; 129(5):1126-36. PubMed ID: 21710495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
    Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
    Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
    Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
    J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
    Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
    Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.